International perspective

Working between European and Asian pharmaceutical markets

Much of our work involves companies on two sides of a border, each with a clear commercial interest and different assumptions about how business is done. Our role is to make that distance manageable.

Europe and India/Asia

Where we are most useful

European companies looking towards India and Asia, and Indian and Asian companies looking towards Europe, rarely fail for lack of interest. They fail on sequencing, expectations and access to the right person.

We work in both directions: identifying counterparties for a European company seeking supply, partners or products, and supporting Indian and Asian manufacturers who want to establish or expand a European commercial presence.

This is practical work — understanding what each side actually needs, whether the commercial logic holds, what a realistic timeline looks like, and where a discussion is likely to stall before it does.

We do not describe ourselves as global. We work in the markets we know, from Germany, and we say plainly when a market is outside our reach.

Market intelligence

International market profiles

Customers are requested to contact us for B2B matchmaking opportunities in the markets below.

Northern & Eastern Europe
Western Europe & Spain–Portugal
DACH & core markets
India, Middle East & Asia

Market Overview

Germany

Germany is Europe’s largest pharmaceutical market and one of its principal chemical and life-science centres. Broad insurance coverage, a large patient base and extensive industrial infrastructure make it a central reference market for European healthcare trade.

Market character: Large, mature, highly regulated
Key segments: Innovative medicines, generics, APIs
Growth direction: Stable, specialty-driven

Pharmaceutical landscape

Research-based companies, generic manufacturers, wholesalers and specialised hospital suppliers operate within a highly structured statutory insurance system.

API & chemicals

Germany has one of Europe’s strongest chemical industries, with capabilities in fine chemicals, pharmaceutical intermediates and selected active ingredients.

Regulation

EU authorisation rules combine with German benefit assessment, reimbursement and pharmacy frameworks. Quality, pharmacovigilance and supply obligations are closely supervised.

Manufacturing & innovation

The country supports finished-dose, biologics, vaccines and advanced-therapy production, alongside strong university, biotech and applied-research networks.

International trade

Germany is a major importer and exporter of pharmaceuticals, APIs and chemicals, with dense logistics links across the EU and global markets.

Outlook

Demand is supported by demographics and specialty care. Cost containment, evidence requirements, supply resilience and digitalisation remain defining trends.

This profile provides general market information only. It is not investment advice, a recommendation or an offer of services in any regulated financial activity.

Partner ecosystem

Specialist capabilities across the value chain

International pharmaceutical activity may draw on a range of independent manufacturers, distributors and professional advisers. This overview explains the types of capabilities that can be relevant; it does not represent a list of Azeta Pharma's current contractual relationships. Select a category to view its general role.

Manufacturing & supply
Commercial & distribution
Regulatory & quality

Commercial & distribution

DACH distribution partners

Role: Distribution capabilities that may support pharmaceutical and healthcare products across Germany, Austria and Switzerland.
Typical areas: Market access support · Distribution infrastructure · Healthcare logistics · Channel coverage · Commercial coordination
Relevance: Distribution specialists can be relevant when assessing local routes to market, product handling requirements and commercial coverage in DACH markets.

Cross-border practice

What crossing a market usually requires

A defined commercial question

Which product, territory, channel or capability is actually at stake, and what would a successful outcome look like commercially.

The right counterparties

A short list of companies with genuine interest and the standing to act, rather than a broad market survey.

Discussions that hold

Preparation on both sides, realistic expectations on price, timing and obligations, and continuity between meetings.

Business cultures

Two markets, two sets of assumptions

Differences in decision-making, documentation, negotiation pace and follow-up are ordinary features of cross-border business, not obstacles. They become problems only when neither side names them.

We stay involved after the introduction: clarifying what has been agreed, keeping momentum between meetings, and translating commercial intent into terms both parties recognise.

Enquiries

Discussing a specific project or market

If you are considering a partnership, a new market or a business development initiative, we are glad to have an initial, confidential conversation about whether we are the right counterpart for it.

Contact Azeta Pharma pharmaazeta@gmail.com